Safety and Efficacy of Laquinimod Versus Placebo for Relapsing Remitting Multiple Sclerosis
- Study Title
- Safety and Efficacy of OrFemale, Maley Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)
- Teva Identifier
- MS-LAQ-301 | EUDRACT 2007-003226-19
- ClinicalTrials.gov Identifier
- NCT00509145
- Study Status
- Completed
- Trial Condition(s)
- Multiple Sclerosis
- Interventions
- Drug: Laquinimod | Other: Placebo
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult
- Age Range
- 18 Years to 55 Years
- Trial Duration
- 12/01/2007 - 12/01/2010
- Phase
- Phase 3
